Project Grant R44CA310522
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,253,869 to Celdara Medical, LLC to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The funding supports advancing CM-HZ01 to the Investigational New Drug (IND) application stage, with the goal of providing a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The project...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Nanocan Therapeutics Corporation in collaboration with Johns Hopkins University, will fund the development and first clinical trial of an innovative Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel technology. The $998,781 award, with a project period from September 2025 to November 2026, aims to extend the use of local radiotherapy from palliative to potential distant...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Rochester provides $639,098 to develop an innovative treatment for metastatic pancreatic cancer. The research aims to overcome both intrinsic and extrinsic barriers to treatment efficacy, specifically by targeting the tumor microenvironment through a combination of local radiotherapy and intratumoral immunotherapy using a novel mRNA-based nanoparticle delivery system. The...
- This federal Project Grant award, totaling $306,200.00, was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to elucidate the molecular mechanisms of oral mucositis damage and repair using a novel oral mucosa chip platform. Key objectives include determining the effects of chemotherapy drugs and fractionated radiotherapy on the oral mucosa, as well as evaluating the single and...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $186,000.00 to The Institute For Cancer Research (ICR) to conduct pilot studies on a new tumor-targeted AURKA (Aurora-A Kinase) inhibitor called NN-01-195. The goal is to investigate the feasibility and potential of this novel chimeric compound, which fuses an HSP90 inhibitor with an AURKA inhibitor, as a cancer treatment approach. The proposed research aims to evaluate the...
- The National Institutes of Health's National Cancer Institute awarded a $662,516 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the federal grant program "Cancer Treatment Research" (CFDA 93.395). The grant, awarded on March 11, 2025, supports a 5-year research project to evaluate how fractionated radiation therapy affects the tumor microenvironment and impacts the delivery of long-circulating chemotherapy agents. The...
- This $306,265 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on September 16, 2025, will fund the preclinical development of VAX024 - a novel, second-generation recombinant bacterial minicell-based targeted oncolytic in situ immunization (ISI) agent. VAX024 is designed to overcome limitations of current oncolytic viral therapies by leveraging the grantee's proprietary delivery technology to generate a sterile, user-friendly oncolytic...
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...